Association Between Plasma Asprosin Levels and Gestational Diabetes Mellitus

References

• Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005;115(3):485–491. doi:10.1172/JCI200524531
   PubMed Web of Science ®Google Scholar
• Grunnet LG, Hansen S, Hjort L, et al. Adiposity, dysmetabolic traits, and earlier onset of female puberty in adolescent offspring of women with gestational diabetes mellitus: a clinical study within the Danish national birth cohort. Diabetes Care. 2017;40(12):1746–1755. doi:10.2337/dc17-0514
   PubMed Web of Science ®Google Scholar
• Bartha JL, Martinez-Del-Fresno P, Comino-Delgado R. Early diagnosis of gestational diabetes mellitus and prevention of diabetes-related complications. Eur J Obstet Gynecol Reprod Biol. 2003;109(1):41–44. doi:10.1016/S0301-2115(02)00480-3
   PubMed Web of Science ®Google Scholar
• Grubu DMCv E. Diabetes Mellitus ve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu [Diagnosis, Treatment and Follow-up Guidelines for Diabetes Mellitus and Its Complications 14th ed]. Grubu DMCv E; 2020.
   Google Scholar
• Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566–579. doi:10.1016/j.cell.2016.02.063
   PubMed Web of Science ®Google Scholar
• Zhong L, Long Y, Wang S, et al. Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: a nested case-control study. Placenta. 2020;93:17–22. doi:10.1016/j.placenta.2020.02.004
   PubMed Web of Science ®Google Scholar
• Mari A, Ahrén B, Pacini G. Assessment of insulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab Care. 2005;8(5):529–533. doi:10.1097/01.mco.0000171130.23441.59
   PubMed Web of Science ®Google Scholar
• Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96–104. doi:10.1016/j.mce.2019.03.001
   PubMed Web of Science ®Google Scholar
• Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):3342. doi:10.3390/ijms19113342
   PubMed Web of Science ®Google Scholar
• Alptekin H, Çizmecioğlu A, Işık H, Cengiz T, Yildiz M, Iyisoy MS. Predicting gestational diabetes mellitus during the first trimester using anthropometric measurements and HOMA-IR. Journal of Endocrinological Investigation. 2016;39(5):577–583. doi:10.1007/s40618-015-0427-z
   PubMed Web of Science ®Google Scholar
• Colomiere M, Permezel M, Lappas M. Diabetes and obesity during pregnancy alter insulin signalling and glucose transporter expression in maternal skeletal muscle and subcutaneous adipose tissue. J Mol Endocrinol. 2010;44(4):213–223. doi:10.1677/JME-09-0091
   PubMed Web of Science ®Google Scholar
• Women’s NCCf, Health Cs. Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. Women’s NCCf, Health Cs; 2008.
   Google Scholar
• Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015;19(1):160–164. doi:10.4103/2230-8210.146874
   PubMedGoogle Scholar
• Endo S, Maeda K, Suto M, et al. Differences in insulin sensitivity in pregnant women with overweight and gestational diabetes mellitus. Gynecol Endocrinol. 2006;22(6):343–349. doi:10.1080/09513590600724836
   PubMed Web of Science ®Google Scholar
• Sonagra AD, Biradar SM, D K, Murthy DSJ. Normal pregnancy – a state of insulin resistance. J Clin Diagnost Res. 2014;8(11):CC01–CC3. doi:10.7860/JCDR/2014/10068.5081
   PubMedGoogle Scholar
• Ryan EA, O’ Sullivan MJ, Skyler JS. Insulin action during pregnancy: studies with the euglycemic clamp technique. Diabetes. 1985;34(4):380–389. doi:10.2337/diab.34.4.380
   PubMed Web of Science ®Google Scholar
• Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444. doi:10.1038/nm.4432
   PubMed Web of Science ®Google Scholar
• Stanley K, Fraser R, Bruce C. Physiological changes in insulin resistance in human pregnancy: longitudinal study with the hyperinsulinaemic euglycaemic clamp technique. Br J Obstet Gynaecol. 1998;105(7):756–759. doi:10.1111/j.1471-0528.1998.tb10207.x
   PubMedGoogle Scholar
• Valensise H, Larciprete G, Vasapollo B, et al. C-peptide and insulin levels at 24–30 weeks’ gestation: an increased risk of adverse pregnancy outcomes? Eur J Obstet Gynecol Reprod Biol. 2002;103(2):130–135. doi:10.1016/S0301-2115(02)00048-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–188. doi:10.1016/j.cca.2017.10.034
   PubMed Web of Science ®Google Scholar
• Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018:9471583. doi:10.1155/2018/9471583
   PubMed Web of Science ®Google Scholar
• Alan M, Gurlek B, Yilmaz A, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(3):220–223. doi:10.1080/09513590.2018.1512967
   PubMed Web of Science ®Google Scholar
• Baykus Y, Yavuzkir S, Ustebay S, Ugur K, Deniz R, Aydin S. Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus. Peptides. 2019;120:170132. doi:10.1016/j.peptides.2019.170132
   PubMed Web of Science ®Google Scholar